US2005095701A1PendingUtilityA1

PNS cell lines and methods of use therefor

60
Assignee: SIGNAL PHARM INCPriority: Apr 14, 1998Filed: Nov 9, 2004Published: May 5, 2005
Est. expiryApr 14, 2018(expired)· nominal 20-yr term from priority
C12N 5/0623C07K 14/82C12N 2510/04A61P 25/00A61P 25/04G01N 33/5058C12N 2740/13043C12N 2503/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Conditionally-immortalized PNS progenitor cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons. The cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of PNS-related diseases. The cell lines and/or differentiated cells may also be used in assays and for the general study of PNS cell development, death and abnormalities.

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled)  
     
     
         47 . A method of transplanting a dorsal root ganglion cell into a mammal, comprising administering to a mammal a cell produced by: 
 (a) transfecting a dorsal root ganglion progenitor cell, plated on a first surface and in a first growth medium that permit proliferation, with DNA encoding a selectable marker and a regulatable oncogene, to produce transfected cells;    (b) passaging said transfected cells onto a second surface and in a second growth medium that permit attachment and proliferation, thereby producing a conditionally-immortalized dorsal root ganglion progenitor cells; and    (c) culturing said conditionally-immortalized dorsal root ganglion progenitor cells under conditions inhibiting expression of the regulatable oncogene.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.